METTL3 and hepatocellular carcinoma: In hepatocellular carcinoma [316], METTL3-mediated m6A modification of EGFR mRNA was shown to drive lenvatinib resistance, while pharmacological inhibition of METTL3 using STM2457 significantly restored drug sensitivity across multiple murine models, suggesting its potential as a combination therapy candidate.